Oxytetracycline Hydrochloride Tablets

Tetracycline antibiotics. This product is a broad-spectrum antibacterial agent. Many Rickettsia, Mycoplasma, Chlamydia, spirochetes, amoebas and some Plasmodium are also sensitive to this product. Enterococci are resistant to it. Others such as Actinomycetes, Bacillus anthracis, Listeria monocytogenes, Clostridium, Nocardia, Vibrio, Brucella, Campylobacter, Yersinia, etc. are sensitive to this product. This product has certain antibacterial activity against gonococci and meningococci, but penicillin-resistant gonococci are also resistant to oxytetracycline. Due to the widespread use of tetracyclines over the years, common clinical pathogens have serious resistance to oxytetracycline, including Gram-positive bacteria such as Staphylococcus and most Gram-negative bacilli. There is cross-resistance between different types of tetracycline antibiotics. Mechanism of action of this product

The main ingredient of this product is oxytetracycline hydrochloride, and its chemical name is 6-methyl-4-(dimethylamino)-3,5,6,10,12,12a-hexahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-2-naphthacenecarboxamide hydrochloride.

This product is a yellow tablet or sugar-coated tablet; it appears yellow after removing the coating.

1 This product can be used as a drug of choice for the following diseases: (1) Rickettsial diseases, including epidemic typhus, endemic typhus, Rocky Mountain fever, scrub typhus and Q fever. (2) Mycoplasma infections. (3) Chlamydia infections, including psittacosis, venereal disease, lymphoedema, nonspecific urethritis, salpingitis, cervicitis and trachoma. (4) Relapsing fever. (5) Brucellosis. (6) Cholera. (7) Tularemia. (8) Plague. (9) Chancroid. It should be used in combination with aminoglycosides to treat brucellosis and plague. 2 Since the common pathogens are currently

Oral administration: 1-2g per day for adults, divided into 3-4 times; 20-40mg/kg per day for children over 8 years old, divided into 4 times. This product is contraindicated for children under 8 years old.

1 Digestive system: Gastrointestinal symptoms such as nausea, vomiting, upper abdominal discomfort, abdominal distension, diarrhea, and pancreatitis. Occasionally, there are reports of esophagitis and esophageal ulcers, which mostly occur in patients who go to bed immediately after taking the medicine. 2 Hepatotoxicity: Usually fatty liver degeneration. Pregnant women and patients with existing renal impairment are prone to hepatotoxicity, but hepatotoxicity can also occur in patients without the above conditions. Tetracycline-induced pancreatitis can also occur simultaneously with hepatotoxicity, and the patient does not have primary liver disease. 3 Allergic reactions: Mostly maculopapular rash and erythema, in addition to urticaria, angioneurotic edema, allergic purpura, pericarditis, and exacerbation of systemic lupus erythematosus can be seen, and exfoliative dermatitis is not common. Occasionally, anaphylactic shock and asthma occur.

Patients with a history of allergy to tetracyclines are contraindicated.

1 When used with antacids such as sodium bicarbonate, the absorption of this product may be reduced and its activity may be reduced due to the increase in gastric pH. Therefore, antacids should not be taken within 1 to 3 hours after taking this product. 2 Drugs containing metal ions such as calcium, magnesium, and iron may form insoluble complexes with this product, reducing the absorption of this product after oral administration. 3 When used in combination with the general anesthetic methoxyflurane, its nephrotoxicity may be enhanced. 4 When used in combination with strong diuretics such as furosemide, renal damage may be aggravated. 5 When used in combination with other hepatotoxic drugs (such as anti-tumor chemotherapy drugs), liver damage may be aggravated. 6 The lipid-lowering drugs colestyramine or colestipol may affect the absorption of this product.

Keep away from light, sealed and stored in a dry place.

Calculated as C22H24N2O9 0.25g

Heilongjiang Yidahong Pharmaceutical Co., Ltd.

• Founded in:

  2021-01-12

• Address:

  No. 21-1, Gongye Street, Hulin City, Jixi City, Heilongjiang Province (declaration commitment)

• Tax NO.:

  91230781MA1CE97561

• Registered Funds:

  60 million yuan

• Email:

  Log in to view